Health Care & Life Sciences » Biotechnology | Staidson

Staidson | Income Statement

Fiscal year is January-December. All values CNY Millions.
2013
2014
2015
2016
2017
2018
Sales/Revenue
885
1,086
1,242
1,396
1,378
799
Cost of Goods Sold (COGS) incl. D&A
44
62
68
70
77
88
Gross Income
841
1,024
1,174
1,326
1,301
711
SG&A Expense
743
854
945
1,066
1,049
627
EBIT
97
169
226
258
252
84
Unusual Expense
-
-
-
25
-
-
Non Operating Income/Expense
7
26
4
-
1
16
Interest Expense
-
-
1
-
1
1
Pretax Income
135
234
243
296
306
152
Income Tax
23
38
34
41
42
17
Equity in Affiliates
-
1
3
1
3
1
Consolidated Net Income
110
195
209
255
260
134
Net Income
110
195
211
257
263
134
Net Income After Extraordinaries
110
195
211
257
263
134
Net Income Available to Common
110
195
211
257
263
134
EPS (Basic)
0.23
0.41
0.45
0.54
0.55
0.28
Basic Shares Outstanding
470
470
469
476
478
477
EPS (Diluted)
0.23
0.42
0.45
0.54
0.55
0.28
Diluted Shares Outstanding
470
470
469
476
478
477
EBITDA
109
187
245
279
277
111
Other Operating Expense
1
2
3
3
-
-
Non-Operating Interest Income
30
36
38
39
53
52
Minority Interest Expense
-
-
2
2
3
-

About Staidson

View Profile
Address
36 Jinghai 2nd Road
Beijing Beijing 100176
China
Employees -
Website http://www.staidson.com
Updated 07/08/2019
Staidson (Beijing) Biopharmaceuticals Co., Ltd. engages in the research, development, production, and sale of independent intellectual property innovation drugs. Its products include mouse nerve growth factor injection, intravenous compound polyethylene glycol electrolyte powder solution, gliclazide, nabumetone, and aspirin. The company was founded on August 16, 2002 and is headquartered in Beijing, China.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.